Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMMP)

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

GlobeNewswire 9 days ago

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

GlobeNewswire 9 days ago

Immutep Quarterly Activities Report Q1 FY25

GlobeNewswire October 29, 2024

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire October 28, 2024

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

GlobeNewswire October 17, 2024

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 10, 2024

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

GlobeNewswire October 3, 2024

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

GlobeNewswire September 24, 2024

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma

GlobeNewswire September 18, 2024
View More News ››

Opinion & Analysis (NDAQ:IMMP)

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Streetwise Reports February 7, 2018
View More Opinion ››

Bullboard Posts (NDAQ:IMMP)

It was a buy for me today,play it again Sam.

I played this one about 5 years ago,and it was time for me to do it again,for it should be a nice triple your money for me with this one...
coolfooldumbguy - July 15, 2024

Immutep Up as Combo Therapy Meets Carcinoma Study Goals | Be

Breaking News: $IMMP Immutep Up as Combo Therapy Meets Carcinoma Study Goals | BenzingaImmutep Limited@(NASDAQ: IMMP) jumped 14.9% after...
whytestocks - July 15, 2024

QS, SWN, IMMP, KEY, NCLH showing five-day upward surge

Breaking News: $IMMP QS, SWN, IMMP, KEY, NCLH showing five-day upward surge2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading...
whytestocks - July 12, 2024

IMMP Price Target Alert: $6.00. Issued by Robert W. Baird

Just In: $IMMP IMMP Price Target Alert: $6.00. Issued by Robert W. Baird2024-06-27 08:00:12 ET Joel Beatty from Robert W. Baird issued a...
whytestocks - June 27, 2024

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring

Just In: $IMMP Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? | BenzingaWednesday,@Immutep Limited@(NASDAQ...
whytestocks - April 24, 2024

it's a buy today for me

at this low price,taking a chance,so glta.
coolfooldumbguy - March 22, 2019
View more Bullboard ››

Mandalay Resources Corp.

Mandalay Resources Corp.

Mandalay Resources Corporation is a Canada-based natural resource company with producing assets in Australia (Costerfield ...
View More »